{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:34:45Z","timestamp":1793205285147,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CORPG3J0301"],"award-info":[{"award-number":["CORPG3J0301"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CORPG3L0451"],"award-info":[{"award-number":["CORPG3L0451"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81973-z","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T08:48:12Z","timestamp":1739868492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM"],"prefix":"10.1038","volume":"15","author":[{"given":"Birdie","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Li","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Ying","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Chang","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang-Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"81973_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"NH Cho","year":"2018","unstructured":"Cho, N. H. et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 138, 271\u2013281. https:\/\/doi.org\/10.1016\/j.diabres.2018.02.023 (2018).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"81973_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MAB Khan","year":"2020","unstructured":"Khan, M. A. B. et al. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J. Epidemiol. Glob. Health 10, 107\u2013111. https:\/\/doi.org\/10.2991\/jegh.k.191028.001 (2020).","journal-title":"J. Epidemiol. Glob. Health"},{"key":"81973_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24, 302\u2013308. https:\/\/doi.org\/10.1681\/ASN.2012070718 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"81973_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","volume":"12","author":"MC Thomas","year":"2016","unstructured":"Thomas, M. C., Cooper, M. E. & Zimmet, P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat. Rev. Nephrol. 12, 73\u201381. https:\/\/doi.org\/10.1038\/nrneph.2015.173 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"81973_CR5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744 (2019).","journal-title":"N. Engl. J. Med."},{"key":"81973_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720 (2015).","journal-title":"N. Engl. J. Med."},{"key":"81973_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816 (2020).","journal-title":"N. Engl. J. Med."},{"key":"81973_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner, C. et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137, 119\u2013129. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028268 (2018).","journal-title":"Circulation"},{"key":"81973_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon, V. et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 22, 104\u2013112. https:\/\/doi.org\/10.1681\/ASN.2010030246 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"81973_CR10","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","volume":"61","author":"MC Thomas","year":"2018","unstructured":"Thomas, M. C. & Cherney, D. Z. I. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61, 2098\u20132107. https:\/\/doi.org\/10.1007\/s00125-018-4669-0 (2018).","journal-title":"Diabetologia"},{"key":"81973_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","volume":"19","author":"L Ni","year":"2020","unstructured":"Ni, L., Yuan, C., Chen, G., Zhang, C. & Wu, X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc. Diabetol. 19, 98. https:\/\/doi.org\/10.1186\/s12933-020-01071-y (2020).","journal-title":"Cardiovasc. Diabetol."},{"key":"81973_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","volume":"28","author":"L Blonde","year":"2022","unstructured":"Blonde, L. et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr. Pract. 28, 923\u20131049. https:\/\/doi.org\/10.1016\/j.eprac.2022.08.002 (2022).","journal-title":"Endocr. Pract."},{"key":"81973_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler, D. C. et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 22\u201331. https:\/\/doi.org\/10.1016\/S2213-8587(20)30369-7 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"81973_CR14","first-page":"24","volume":"78","author":"P Delanaye","year":"2023","unstructured":"Delanaye, P. & Scheen, A. J. EMPA-KIDNEY: empagliflozin in chronic kidney disease. Rev. Med. Liege. 78, 24\u201328 (2023).","journal-title":"Rev. Med. Liege."},{"key":"81973_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1053\/j.ajkd.2017.12.006","volume":"72","author":"AA House","year":"2018","unstructured":"House, A. A. Management of heart failure in advancing CKD: Core curriculum 2018. Am. J. Kidney. Dis. 72, 284\u2013295. https:\/\/doi.org\/10.1053\/j.ajkd.2017.12.006 (2018).","journal-title":"Am. J. Kidney. Dis."},{"key":"81973_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.kint.2024.01.002","volume":"105","author":"JJ Chen","year":"2024","unstructured":"Chen, J. J., Lee, T. H. & Yang, H. Y. Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists. Kidney Int. 105, 442\u2013444. https:\/\/doi.org\/10.1016\/j.kint.2024.01.002 (2024).","journal-title":"Kidney Int."},{"key":"81973_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/sdi.12832","volume":"32","author":"EA Oliveira","year":"2019","unstructured":"Oliveira, E. A., Zheng, R., Carter, C. E. & Mak, R. H. Cachexia\/Protein energy wasting syndrome in CKD: Causation and treatment. Semin. Dial. 32, 493\u2013499. https:\/\/doi.org\/10.1111\/sdi.12832 (2019).","journal-title":"Semin. Dial."},{"key":"81973_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/toxins12060361","volume":"12","author":"M Diaz-Ricart","year":"2020","unstructured":"Diaz-Ricart, M. et al. Endothelial damage, inflammation and immunity in chronic kidney disease. Toxins (Basel) 12, 361. https:\/\/doi.org\/10.3390\/toxins12060361 (2020).","journal-title":"Toxins (Basel)"},{"key":"81973_CR19","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2018062","volume":"40","author":"LY Lin","year":"2018","unstructured":"Lin, L. Y., Warren-Gash, C., Smeeth, L. & Chen, P. C. Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol. Health 40, e2018062. https:\/\/doi.org\/10.4178\/epih.e2018062 (2018).","journal-title":"Epidemiol. Health"},{"key":"81973_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh, C. Y. et al. Taiwan\u2019s National Health Insurance Research Database: past and future. Clin. Epidemiol. 11, 349\u2013358. https:\/\/doi.org\/10.2147\/CLEP.S196293 (2019).","journal-title":"Clin. Epidemiol."},{"key":"81973_CR21","doi-asserted-by":"publisher","first-page":"e3388","DOI":"10.1097\/MD.0000000000003388","volume":"95","author":"MS Hsieh","year":"2016","unstructured":"Hsieh, M. S. et al. Contrast medium exposure during computed tomography and risk of development of end-stage renal disease in patients with chronic kidney disease: A nationwide population-based, propensity score-matched, longitudinal follow-up study. Med. (Baltim.) 95, e3388. https:\/\/doi.org\/10.1097\/MD.0000000000003388 (2016).","journal-title":"Med. (Baltim.)"},{"key":"81973_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189126","volume":"12","author":"CC Lin","year":"2017","unstructured":"Lin, C. C. et al. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade. PLoS One 12, e0189126. https:\/\/doi.org\/10.1371\/journal.pone.0189126 (2017).","journal-title":"PLoS One"},{"key":"81973_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jfma.2013.09.009","volume":"114","author":"CY Hsieh","year":"2015","unstructured":"Hsieh, C. Y., Chen, C. H., Li, C. Y. & Lai, M. L. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J. Formos. Med. Assoc. 114, 254\u2013259. https:\/\/doi.org\/10.1016\/j.jfma.2013.09.009 (2015).","journal-title":"J. Formos. Med. Assoc."},{"key":"81973_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2015.07.075","volume":"201","author":"CL Cheng","year":"2015","unstructured":"Cheng, C. L., Chien, H. C., Lee, C. H., Lin, S. J. & Yang, Y. H. Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int. J. Cardiol. 201, 96\u2013101. https:\/\/doi.org\/10.1016\/j.ijcard.2015.07.075 (2015).","journal-title":"Int. J. Cardiol."},{"key":"81973_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2188\/jea.je20140076","volume":"24","author":"CL Cheng","year":"2014","unstructured":"Cheng, C. L. et al. Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. J. Epidemiol. 24, 500\u2013507. https:\/\/doi.org\/10.2188\/jea.je20140076 (2014).","journal-title":"J. Epidemiol."},{"key":"81973_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm. Stat. 10, 150\u2013161. https:\/\/doi.org\/10.1002\/pst.433 (2011).","journal-title":"Pharm. Stat."},{"key":"81973_CR27","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/sim.4264","volume":"30","author":"X Zhang","year":"2011","unstructured":"Zhang, X., Zhang, M. J. & Fine, J. A proportional hazards regression model for the subdistribution with right-censored and left-truncated competing risks data. Stat. Med. 30, 1933\u20131951. https:\/\/doi.org\/10.1002\/sim.4264 (2011).","journal-title":"Stat. Med."},{"key":"81973_CR28","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/sim.4200","volume":"30","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Stat. Med. 30, 1292\u20131301. https:\/\/doi.org\/10.1002\/sim.4200 (2011).","journal-title":"Stat. Med."},{"key":"81973_CR29","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.84353","volume":"17","author":"S Rabizadeh","year":"2019","unstructured":"Rabizadeh, S., Nakhjavani, M. & Esteghamati, A. Cardiovascular and renal benefits of SGLT2 Inhibitors: A narrative review. Int. J. Endocrinol. Metab. 17, e84353. https:\/\/doi.org\/10.5812\/ijem.84353 (2019).","journal-title":"Int. J. Endocrinol. Metab."},{"key":"81973_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.diabres.2017.06.018","volume":"130","author":"S Gadzhanova","year":"2017","unstructured":"Gadzhanova, S., Pratt, N. & Roughead, E. Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program. Diabetes Res. Clin. Pract. 130, 180\u2013185. https:\/\/doi.org\/10.1016\/j.diabres.2017.06.018 (2017).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"81973_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pcd.2017.06.004","volume":"12","author":"KY Thong","year":"2018","unstructured":"Thong, K. Y. et al. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit. Prim. Care Diabetes 12, 45\u201350. https:\/\/doi.org\/10.1016\/j.pcd.2017.06.004 (2018).","journal-title":"Prim. Care Diabetes"},{"key":"81973_CR32","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1185\/03007995.2014.890925","volume":"30","author":"P Nyirjesy","year":"2014","unstructured":"Nyirjesy, P. et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr. Med. Res. Opin. 30, 1109\u20131119. https:\/\/doi.org\/10.1185\/03007995.2014.890925 (2014).","journal-title":"Curr. Med. Res. Opin."},{"key":"81973_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/medicines9120059","volume":"9","author":"S Uitrakul","year":"2022","unstructured":"Uitrakul, S., Aksonnam, K., Srivichai, P., Wicheannarat, S. & Incomenoy, S. The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study. Med. (Basel) 9, 59. https:\/\/doi.org\/10.3390\/medicines9120059 (2022).","journal-title":"Med. (Basel)"},{"key":"81973_CR34","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1016\/j.ekir.2021.05.025","volume":"6","author":"EC Lorenz","year":"2021","unstructured":"Lorenz, E. C. et al. Frailty in CKD and transplantation. Kidney Int. Rep. 6, 2270\u20132280. https:\/\/doi.org\/10.1016\/j.ekir.2021.05.025 (2021).","journal-title":"Kidney Int. Rep."},{"key":"81973_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/1471-2369-14-228","volume":"14","author":"SR Walker","year":"2013","unstructured":"Walker, S. R. et al. Association of frailty and physical function in patients with non-dialysis CKD: a systematic review. BMC Nephrol. 14, 228. https:\/\/doi.org\/10.1186\/1471-2369-14-228 (2013).","journal-title":"BMC Nephrol."},{"key":"81973_CR36","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau, K., Dharia, A., Alrowiyti, I. & Cherney, D. Z. I. Prescribing SGLT2 inhibitors in patients with CKD: Expanding indications and practical considerations. Kidney Int. Rep. 7, 1463\u20131476. https:\/\/doi.org\/10.1016\/j.ekir.2022.04.094 (2022).","journal-title":"Kidney Int. Rep."},{"key":"81973_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","volume":"93","author":"DZI Cherney","year":"2018","unstructured":"Cherney, D. Z. I. et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 93, 231\u2013244. https:\/\/doi.org\/10.1016\/j.kint.2017.06.017 (2018).","journal-title":"Kidney Int."},{"key":"81973_CR38","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286 (2022).","journal-title":"N. Engl. J. Med."},{"key":"81973_CR39","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190 (2020).","journal-title":"N. Engl. J. Med."}],"updated-by":[{"DOI":"10.1038\/s41598-025-96996-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81973-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81973-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81973-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T10:33:36Z","timestamp":1744367616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81973-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["81973"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81973-z","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-025-96996-3","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"25 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-96996-3","URL":"https:\/\/doi.org\/10.1038\/s41598-025-96996-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors disclosure there is no financial conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5872"}}